首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1954787篇
  免费   143170篇
  国内免费   6092篇
耳鼻咽喉   25953篇
儿科学   61459篇
妇产科学   53062篇
基础医学   278826篇
口腔科学   57612篇
临床医学   173156篇
内科学   384295篇
皮肤病学   44990篇
神经病学   150907篇
特种医学   73975篇
外国民族医学   318篇
外科学   297556篇
综合类   45609篇
现状与发展   5篇
一般理论   582篇
预防医学   136431篇
眼科学   47017篇
药学   146596篇
  8篇
中国医学   6349篇
肿瘤学   119343篇
  2021年   15716篇
  2019年   16071篇
  2018年   23611篇
  2017年   17907篇
  2016年   19829篇
  2015年   22844篇
  2014年   31348篇
  2013年   44449篇
  2012年   61893篇
  2011年   64722篇
  2010年   38290篇
  2009年   35828篇
  2008年   59391篇
  2007年   63090篇
  2006年   63131篇
  2005年   59879篇
  2004年   57289篇
  2003年   54371篇
  2002年   52132篇
  2001年   107463篇
  2000年   109808篇
  1999年   90873篇
  1998年   23240篇
  1997年   20109篇
  1996年   19825篇
  1995年   19003篇
  1994年   17266篇
  1993年   15887篇
  1992年   67221篇
  1991年   64479篇
  1990年   61832篇
  1989年   59593篇
  1988年   54077篇
  1987年   52647篇
  1986年   49217篇
  1985年   46580篇
  1984年   33944篇
  1983年   28611篇
  1982年   15681篇
  1979年   29301篇
  1978年   19932篇
  1977年   17018篇
  1976年   15488篇
  1975年   16459篇
  1974年   19895篇
  1973年   19051篇
  1972年   17811篇
  1971年   16553篇
  1970年   15293篇
  1969年   14466篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).

Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.

Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).

Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).

Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.

Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED.  相似文献   
112.
113.
114.
115.
A 17‐year‐old boy presented with recurring severe dermatitis of the face of 5‐months duration that resembled impetigo. He had been treated with several courses of antibiotics without improvement. Biopsy showed changes consistent with allergic contact dermatitis and patch testing later revealed sensitization to benzoyl peroxide, which the patient had been using for the treatment of acne vulgaris.  相似文献   
116.
117.
118.
119.
Investigative studies of white matter (WM) brain structures using diffusion MRI (dMRI) tractography frequently require manual WM bundle segmentation, often called “virtual dissection.” Human errors and personal decisions make these manual segmentations hard to reproduce, which have not yet been quantified by the dMRI community. It is our opinion that if the field of dMRI tractography wants to be taken seriously as a widespread clinical tool, it is imperative to harmonize WM bundle segmentations and develop protocols aimed to be used in clinical settings. The EADC‐ADNI Harmonized Hippocampal Protocol achieved such standardization through a series of steps that must be reproduced for every WM bundle. This article is an observation of the problematic. A specific bundle segmentation protocol was used in order to provide a real‐life example, but the contribution of this article is to discuss the need for reproducibility and standardized protocol, as for any measurement tool. This study required the participation of 11 experts and 13 nonexperts in neuroanatomy and “virtual dissection” across various laboratories and hospitals. Intra‐rater agreement (Dice score) was approximately 0.77, while inter‐rater was approximately 0.65. The protocol provided to participants was not necessarily optimal, but its design mimics, in essence, what will be required in future protocols. Reporting tractometry results such as average fractional anisotropy, volume or streamline count of a particular bundle without a sufficient reproducibility score could make the analysis and interpretations more difficult. Coordinated efforts by the diffusion MRI tractography community are needed to quantify and account for reproducibility of WM bundle extraction protocols in this era of open and collaborative science.  相似文献   
120.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号